Why ImmunityBio (IBRX) Is Up 13.5% After Strong Q3 Anktiva Revenue Surge Announced at Jefferies London

Simply Wall St
  • ImmunityBio, Inc. recently presented at the Jefferies London Healthcare Conference 2025, sharing updates on its latest performance and product developments at the ME Hotel in London.
  • A noteworthy highlight was the company’s significant third-quarter product revenue growth, driven by strong commercial demand for Anktiva in combination with BCG for BCG-unresponsive NMIBC with CIS.
  • We’ll explore how robust Anktiva product uptake and higher revenue impact ImmunityBio’s investment narrative and outlook.

These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

What Is ImmunityBio's Investment Narrative?

For anyone considering ImmunityBio today, the core investment thesis rests on the commercial promise and real-world uptake of Anktiva, particularly after its momentum shown in third-quarter earnings and at the recent Jefferies London Healthcare Conference. The company is now seeing robust product revenue and a narrowing net loss, both positive developments that could shift the focus toward revenue acceleration and upcoming product milestones as primary short-term catalysts. This latest news may slightly reduce the perception of execution risk, particularly around launch uptake, but does not eliminate key concerns, funding remains front-of-mind given less than a year’s cash runway, and the company is still unprofitable with notably high and increasing losses in recent years. The path to profitability and sustainable cash flow, often reliant on hitting further clinical and regulatory milestones, remains a central risk and will likely weigh on investor sentiment even in the face of strong product demand. On the other hand, limited cash reserves may still raise questions despite recent operational improvements.

ImmunityBio's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

IBRX Community Fair Values as at Nov 2025
The Simply Wall St Community's fair value estimates for ImmunityBio differ sharply, ranging from as low as US$0.33 to US$15.92, with ten opinions embodied. While some see extreme upside, others remain cautious, underscoring how the company’s slim cash runway and recent strong product sales are shaping alternate scenarios for future performance. Explore these varied outlooks and see how your view aligns.

Explore 10 other fair value estimates on ImmunityBio - why the stock might be worth less than half the current price!

Build Your Own ImmunityBio Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

Ready For A Different Approach?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if ImmunityBio might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com